Jennifer M. Brannan

TL;DR: The authors found that FDA-approved selective estrogen receptor modulators (SERMs), which have many uses that range from fertility treatments to breast cancer therapy, could inhibit EBOV infection both in vitro and in a mouse model, and these data support the screening of readily available approved drugs to identify therapeutics for the Ebola viruses and other infectious diseases.

TL;DR: The discovery that AP1 and AP2 cotraffic with HCV particles in live cells is discovered and a proof of principle for a repurposed, host-targeted approach to combat emerging viruses is established.

TL;DR: Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity, and this framework identifies functional correlates that can inform therapeutic and vaccine design strategies against EBOV and other pathogens.

TL;DR: This comprehensive dataset provides a rubric to evaluate novel antibodies and vaccine responses and a roadmap for therapeutic development for EBOV and related viruses.

TL;DR: An immunization-elicited macaque antibody that clamps the internal fusion loop with the N terminus of the ebolavirus glycoproteins and potently neutralizes Ebola, Sudan, Bundibugyo, and Reston viruses is described.